News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Axsome Therapeutics‘ AXS-05, an investigational oral therapy for the treatment of agitation in people with Alzheimer’s disease. This designation is intended to accelerate the development and review of potential…

Scientists used a new imaging technique to assess the structure of amyloid-beta aggregates — known culprits in Alzheimer’s development — that are present inside nerve cells at early stages of the disease, a study reports. These findings, from a mouse model, may…

Experiments on the International Space Station showed gravity affects the formation of amyloids, the pathological tangles of proteins found in the brains of those with Alzheimer’s disease. Both the speed by which they formed and the structure they took in microgravity differed from amyloids formed through similar means in…

Anavex Life Sciences will expand its Phase 2b/3 clinical trial testing the efficacy and safety of Anavex 2-73 (blarcamesine) for the treatment of early Alzheimer’s disease into Canada and the United Kingdom (U.K.) following the go-ahead from…

Neurotrope has announced the launch of a Phase 2 clinical trial to investigate the long-term use of bryostatin-1 for moderate and moderately severe Alzheimer’s disease.  The company expects to dose the first patient later this year.

“The Longest Day” is the summer solstice — the day with the most light — which falls this year on June 20. It’s also the day each year that people all over world battle “the darkness of Alzheimer’s” through fundraising for the Alzheimer’s Association (AA). All proceeds raised…

A type of mouth bacteria involved in gum disease is able to infect human brain cells, new research shows. The infection results in cellular changes that are similar to what is seen in Alzheimer’s, supporting a link between the bacteria and the neurodegenerative disease. The findings were presented at…

The U.S. Food and Drug Administration (FDA) has approved Tauvid (flortaucipir F18) as an imaging radiotracer agent — a radioactive diagnostic tool — to efficiently detect clumps of tau protein in the brain, one of the hallmarks of Alzheimer’s disease. “Alzheimer’s disease is a devastating condition that affects millions…

Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from a Phase 2b clinical trial. The company announced it will study these topline data in deciding next…

Axsome Therapeutics‘ investigational oral therapy AXS-05 significantly and rapidly lessened agitation in patients with Alzheimer’s disease, top-line results from a Phase 2/3 trial show. The therapy also was found to be generally well-tolerated and safe, without affecting cognition. “I am very…